Showing results (111-120 of 119) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 119 results.
Med (New York, N.Y.)|June 13, 2024
First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trialZi-Xian Wang, Junjie Peng, Xinjun Liang, et al.
Arthritis Research & Therapy|April 3, 2016
Colony-stimulating factor (CSF) 1 receptor blockade reduces inflammation in human and murine models of rheumatoid arthritisSamuel Garcia, Linda M Hartkamp, B Malvar-Fernandez, et al.
Ebiomedicine|July 3, 2015
An Analysis of Immunoreactive Signatures in Early Stage Hepatocellular CarcinomaYu Hong, Jiang Long, Hai Li, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|January 23, 2016
[A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer]Binghe Xu, Fuguo Tian, Jingrui Yu, et al.
The Lancet. Gastroenterology & Hepatology|May 10, 2021
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialShukui Qin, Qiu Li, Shanzhi Gu, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2021
Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphomaDan Liu, Chunguang Ma, Ping Lu, et al.
Translational Lung Cancer Research|February 4, 2020
Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancerYunpeng Yang, Bin Wu, Linian Huang, et al.
Signal Transduction and Targeted Therapy|August 6, 2025
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trialChuanhua Zhao, Yanqiao Zhang, Gang Wang, et al.
Nature Medicine|January 22, 2025
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Yanqiao Zhang, Ziyu Li, et al.
Pageof 12